Inventor
Intellectual Property
- PCT Application No. PCT/US2011/048481
Available for
- Exclusive Licensing
- Non-exclusive Licensing
- Scientific Collaboration
Confidential Disclosure Agreement
For more information, please contact:
Justin Levy
Licensing Associate
504-988-6962
jlevy5@tulane.edu
Biomarker-based Diagnostic to Help Determine Cancer Treatment (printable)
Tulane University is actively seeking commercial entities to further develop and commercialize a novel biomarker-based diagnostic to help determine the aggressiveness of a patient's cancer and the types of treatment that may be most effective.
Applications
- Assessing tumor prolificacy and invasiveness
- Assessing whether chemotherapy will be part of an effective treatment
Advantages
- Predicts prognosis and efficacy of treatment plans
- Provides oncologists with direction for treatment plan
- Decreases treatment costs for patients and insurers
Development Status
This technology has been tested extensively in vitro. Laboratory work is ongoing for further data and to understand other predictive capabilities of the biomarker.
Related Publication
Tulane University, New Orleans, LA 70118 504-865-5000 website@tulane.edu